Literature DB >> 512040

Significance of serum complement levels in patients with gastrointestinal disease.

I N Ross, R A Thompson, R D Montgomery, P Asquith.   

Abstract

Levels of the serum complement components, C3 and C4, in patients with Crohn's disease, ulcerative colitis, and miscellaneous gastrointestinal disorders were compared with those of normal blood donors. Significant increases of both components were found in all three patient groups, the highest being in patients with Crohn's disease. Generally, levels of C3 and C4 were lower in patients with inactive rather than active Crohn's disease and ulcerative colitis. These results provide some evidence in support of an immunological basis for inflammatory bowel disease. However, in view of the frequent elevation of C3 and C4 in other gastrointestinal diseases, it is equally possible that the complement components are behaving as acute phase proteins.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 512040      PMCID: PMC1145812          DOI: 10.1136/jcp.32.8.798

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  13 in total

1.  The alternate complement pathway in inflammatory bowel disease. Quantitation of the C3 proactivator (factor B) protein.

Authors:  P A Feinstein; S R Kaplan; W R Thayer
Journal:  Gastroenterology       Date:  1976-02       Impact factor: 22.682

2.  Persistence of serum complement in sera of patients with ulcerative colitis.

Authors:  W R THAYER; H M SPIRO
Journal:  J Lab Clin Med       Date:  1963-07

3.  The clinical significance of seromucoids in regional ileitis and ulcerative colitis.

Authors:  W T COOKE; D I FOWLER; E V COX; R GADDIE; M J MEYNELL
Journal:  Gastroenterology       Date:  1958-05       Impact factor: 22.682

4.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

5.  Evidence of cytotoxicity in ulcerative colitis from immunofluorescent staining of the rectal mucosa.

Authors:  J Ballard; M Shiner
Journal:  Lancet       Date:  1974-05-25       Impact factor: 79.321

6.  Evidence for complement-binding immune complexes in adult coeliac disease, Crohn's disease, and ulcerative colitis.

Authors:  W F Doe; C C Booth; D L Brown
Journal:  Lancet       Date:  1973-02-24       Impact factor: 79.321

7.  C3 proactivator (C3PA) as an acute phase reactant.

Authors:  M Schutte; R DiCamelli; P Murphy; M Sadove; H Gewurz
Journal:  Clin Exp Immunol       Date:  1974-10       Impact factor: 4.330

8.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

9.  Humoral immune system in inflammatory bowel disease: I. Complement levels.

Authors:  H J Hodgson; B J Potter; D P Jewell
Journal:  Gut       Date:  1977-09       Impact factor: 23.059

10.  Short-term course and prognosis of Crohn's disease.

Authors:  F T De Dombal; I L Burton; S E Clamp; J C Goligher
Journal:  Gut       Date:  1974-06       Impact factor: 23.059

View more
  2 in total

1.  Determination of serum bactericidal activity with the aid of luminous bacteria.

Authors:  M Barak; S Ulitzur; D Merzbach
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

Review 2.  Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases.

Authors:  Ramnik J Xavier; Curtis Huttenhower; Jason Lloyd-Price; Cesar Arze; Ashwin N Ananthakrishnan; Melanie Schirmer; Julian Avila-Pacheco; Tiffany W Poon; Elizabeth Andrews; Nadim J Ajami; Kevin S Bonham; Colin J Brislawn; David Casero; Holly Courtney; Antonio Gonzalez; Thomas G Graeber; A Brantley Hall; Kathleen Lake; Carol J Landers; Himel Mallick; Damian R Plichta; Mahadev Prasad; Gholamali Rahnavard; Jenny Sauk; Dmitry Shungin; Yoshiki Vázquez-Baeza; Richard A White; Jonathan Braun; Lee A Denson; Janet K Jansson; Rob Knight; Subra Kugathasan; Dermot P B McGovern; Joseph F Petrosino; Thaddeus S Stappenbeck; Harland S Winter; Clary B Clish; Eric A Franzosa; Hera Vlamakis
Journal:  Nature       Date:  2019-05-29       Impact factor: 49.962

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.